<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03483103</url>
  </required_header>
  <id_info>
    <org_study_id>017006</org_study_id>
    <nct_id>NCT03483103</nct_id>
  </id_info>
  <brief_title>Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy (TRANSCEND-PILOT-017006)</brief_title>
  <official_title>A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Juno Therapeutics, a Subsidiary of Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Juno Therapeutics, a Subsidiary of Celgene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, open-label, multicenter study to determine the efficacy and safety of
      lisocabtagene maraleucel (JCAR017) in adult subjects who have relapsed from, or are
      refractory to, a single line of immunochemotherapy for aggressive B-cell non-Hodgkin lymphoma
      (NHL) and are ineligible for hematopoietic stem cell transplant (based on age, performance
      status, and/or comorbidities). Subjects will receive treatment with lisocabtagene maraleucel
      and will be followed for 2 years for safety, pharmacokinetics and biomarkers, disease status,
      quality of life, and survival.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 26, 2018</start_date>
  <completion_date type="Anticipated">July 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antitumor activity</measure>
    <time_frame>Through Month 24</time_frame>
    <description>Overall response rate (complete response + partial response) based on &quot;Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>90 days</time_frame>
    <description>Proportion of subjects experiencing adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Laboratory abnormalities</measure>
    <time_frame>90 days</time_frame>
    <description>Proportion of subjects experiencing laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity</measure>
    <time_frame>Through Month 24</time_frame>
    <description>Complete response rate based on &quot;Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antitumor activity</measure>
    <time_frame>Through Month 24</time_frame>
    <description>Duration of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum concentration (Cmax) of lisocabtagene maraleucel in blood</measure>
    <time_frame>Through Month 24</time_frame>
    <description>Maximum concentration of lisocabtagene maraleucel in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of the maximum concentration (Tmax) of lisocabtagene maraleucel in blood</measure>
    <time_frame>Through Month 24</time_frame>
    <description>Time of the maximum concentration of lisocabtagene maraleucel in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of (AUC) lisocabtagene maraleucel concentration in blood</measure>
    <time_frame>Through Month 24</time_frame>
    <description>Area under the curve of lisocabtagene maraleucel in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Through Month 24</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>Through Month 24</time_frame>
    <description>Event-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Through Month 24</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life and health economics and outcomes research</measure>
    <time_frame>Through Month 24</time_frame>
    <description>The European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 is a validated quality of life measure applicable to subjects with any cancer diagnosis. It is composed of 30 items that address general physical symptoms, physical functioning, fatigue and malaise, and social and emotional functioning. Subscale scores are transformed to a 0 to 100 scale, with higher scores on functional scales indicating better function and higher scores on symptom scales indicating worse symptoms. A 10 point change in the scoring is considered to be a meaningful change in HRQoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life and health economics and outcomes research</measure>
    <time_frame>Through Month 24</time_frame>
    <description>The EuroQol-5D (EQ-5D) is a standardized measure of health status developed by the EuroQol Group in order to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of the EQ-5D-5L descriptive system and the EQ Visual Analogue scale (EQ VAS). The descriptive system comprises dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels (no problems, slight problems, moderate problems, severe problems, extreme problems). The VAS rating scale is a vertical 20 cm visual analogue scale with the end points labeled best imaginable health state at the top and worst imaginable health state at the bottom having numeric values of 100 and 0 respectively. The participant is asked to indicate his/her health state by ticking (or placing a cross) in the box against the most appropriate statement in each of the 5 dimensions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life and health economics and outcomes research</measure>
    <time_frame>Through month 24</time_frame>
    <description>The Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) consists of the FACT-General scale and a 15-item lymphoma-specific additional concerns subscale (LYM). This scale addresses symptoms and functional limitations that are important to lymphoma patients. Only the LYM subscale will be administered in this study. The LYM items are scored on a 0 (&quot;Not at all&quot;) to 4 (&quot;Very much&quot;) response scale. Items are aggregated to a single score on a 0-60 scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life and health economics and outcomes research</measure>
    <time_frame>Through Month 24</time_frame>
    <description>Numbers of intensive care unit inpatient days and non-ICU inpatient days and reasons for hospitalization</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Lymphoma, Nonhodgkin</condition>
  <condition>Lymphoma, B-Cell</condition>
  <condition>Lymphoma, Large B-Cell, Diffuse</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lisocabtagene maraleucel at a dose of 100×10^6 CAR+ T cells (50×10^6 CD8+ CAR+ T cells and 50×10^6 CD4+ CAR+ T cells), will be given IV in a single-dose schedule on Day 1 (between 2 and 7 days following the completion of lymphodepleting chemotherapy).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>lisocabtagene maraleucel</intervention_name>
    <description>lisocabtagene maraleucel will be administered as a single dose intravenous (IV) injection</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>JCAR017</other_name>
    <other_name>liso-cel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmation of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma of the
             following histology at relapse: diffuse large B-cell lymphoma (DLBCL), not otherwise
             specified (NOS; de novo or transformed follicular lymphoma [tFL]), high-grade B-cell
             lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology
             (double/triple hit lymphoma [DHL/THL]), and follicular lymphoma Grade 3B per WHO 2016
             classification

          -  Previous treatment must include treatment with a single line of chemoimmunotherapy
             containing an anthracycline and a CD20-targeted agent

          -  Subjects must be deemed ineligible for both high-dose chemotherapy and hematopoietic
             stem cell transplant (based on age, performance status and/or comorbidities) while
             also having adequate organ function for CAR T cell treatment.

          -  Positron emission tomography (PET)-positive disease

          -  Histological confirmation of diagnosis at last relapse. Enough tumor material must be
             available for central confirmation of diagnosis, otherwise a new tumor biopsy is
             mandated.

          -  ECOG performance status of 0, or 1, or 2

          -  Adequate vascular access for leukapheresis procedure (either peripheral line or
             surgically-placed line)

          -  Subjects must agree to use appropriate contraception

          -  Subjects must agree to not donate blood, organs, semen, and egg cells for usage in
             other individuals for at least 1 year following lymphodepleting chemotherapy

        Exclusion Criteria:

          -  Subjects with central nervous system (CNS)-only involvement by malignancy (note:
             subjects with secondary CNS involvement are allowed on study)

          -  History of another primary malignancy that has not been in remission for at least 2
             years.

          -  Previous treatment with CD19-targeted therapy, with the exception of prior
             lisocabtagene maraleucel treatment in this protocol for subjects receiving retreatment

          -  Active hepatitis B or hepatitis C infection at the time of screening

          -  History of or active human immunodeficiency virus (HIV) infection at the time of
             screening

          -  Uncontrolled systemic fungal, bacterial, viral or other infection despite appropriate
             antibiotics or other treatment at the time of leukapheresis or lisocabtagene
             maraleucel administration

          -  History of any one of the following cardiovascular conditions within the past 6
             months: Class III or IV heart failure as defined by the New York Heart Association,
             cardiac angioplasty or stenting, myocardial infarction, unstable angina, or other
             clinically significant cardiac disease

          -  History or presence of clinically relevant CNS pathology

          -  Pregnant or nursing women

          -  Subject does not meet protocol-specified washout periods for prior treatments

          -  Prior hematopoietic stem cell transplant

          -  Progressive vascular tumor invasion, thrombosis, or embolism

          -  Venous thrombosis or embolism not managed on stable regimen of anticoagulation

          -  Uncontrolled medical, psychological, familial, sociological, or geographical
             conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nick Trede, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Juno Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Associate Director Clinical Trial Disclosure</last_name>
    <phone>1-888-260-1599</phone>
    <email>clinicaltrialdisclosure@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rajneesh Nath, MD</last_name>
      <phone>480-256-3223</phone>
      <email>Rajneesh.nath@bannerhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UNC School of Medicine</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Bishop</last_name>
      <phone>310-794-6500</phone>
      <email>rbishop@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Herbert Eradat, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Hematology and Oncology</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sutter Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Sharkey</last_name>
      <phone>916-454-6962</phone>
      <email>sharkeym@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Michael Carroll, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Genetics Clinic</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Iglesias</last_name>
      <phone>650-736-0912</phone>
      <email>miglesias@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Neel Gupta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Blood and Marrow Transplant Group of Georgia</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey Brown</last_name>
      <phone>404-851-8238</phone>
      <email>stacey.brown@northside.com</email>
    </contact>
    <investigator>
      <last_name>Scott Solomon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Ackatz</last_name>
      <phone>312-695-3527</phone>
      <email>lori.ackatz@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Leo Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1470</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago Comprehensive Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia Kirvaitis</last_name>
      <phone>773-834-3848</phone>
      <email>pkirvaitis@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Riedell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky/Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Hildebrandt, MD</last_name>
      <phone>859-257-3379</phone>
    </contact>
    <investigator>
      <last_name>Gerhard Hildebrandt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute - Brownsboro</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Haycraft</last_name>
      <phone>502-899-3366</phone>
      <phone_ext>19287</phone_ext>
      <email>dana.haycraft@nortonhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Don Stevens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC School of Medicine</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Oncology Center Bunting Blaustein Building</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lesley Donoho-Cohen, RN</last_name>
      <phone>410-614-0482</phone>
      <email>Ldonoho1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Nina Wagner-Johnston, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates</name>
      <address>
        <city>East Brunswick</city>
        <state>New Jersey</state>
        <zip>08816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Percy Yeung</last_name>
      <phone>732-390-7750</phone>
      <phone_ext>3378</phone_ext>
      <email>pyeung@regionalcancercare.org</email>
    </contact>
    <investigator>
      <last_name>Edward Licitra, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC School of Medicine</name>
      <address>
        <city>East Brunswick</city>
        <state>New Jersey</state>
        <zip>08816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology - Albany Cancer Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Brignull</last_name>
      <phone>518-262-2768</phone>
      <email>susan.brignull@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Courtney Bellomo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology P.C.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Rochester Cancer Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delaney Dretto</last_name>
      <phone>585-275-5825</phone>
      <email>delaney_dretto@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Reagan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doug Hart</last_name>
      <phone>513-751-2273</phone>
      <phone_ext>42401</phone_ext>
      <email>douglas.hart@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>James Essell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Cancer Center/Earle A. Chiles Res. Inst.</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neysa Dagostino</last_name>
      <phone>503-215-2608</phone>
      <email>neysa.dagostino@providence.org</email>
    </contact>
    <investigator>
      <last_name>John Godwin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Greenville Health System - Cancer Institute - Faris Road</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Roman</last_name>
      <phone>864-242-2720</phone>
      <email>sara.roman@prismahealth.org</email>
    </contact>
    <investigator>
      <last_name>Suzanne Fanning, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UNC School of Medicine</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Intermountain Healthcare - LDS Hospital Blood and Marrow Transplant</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelby Kirby</last_name>
      <phone>801-408-2058</phone>
      <email>shelby.kirby@imail.org</email>
    </contact>
    <investigator>
      <last_name>Daanish Hoda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intermountain Healthcare - LDS Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Reynolds</last_name>
      <phone>253-200-3147</phone>
      <email>jreynolds@nwmsonline.com</email>
    </contact>
    <investigator>
      <last_name>Francis Senecal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC School of Medicine</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin, Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kaylee Meisinger</last_name>
      <phone>414-805-8926</phone>
      <email>kmeisinger@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Sayed Mehdi Hamadani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC School of Medicine</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 23, 2018</study_first_submitted>
  <study_first_submitted_qc>March 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2018</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>JCAR017</keyword>
  <keyword>lisocabtagene maraleucel</keyword>
  <keyword>NHL</keyword>
  <keyword>chimeric antigen receptor</keyword>
  <keyword>CAR</keyword>
  <keyword>CAR T cell</keyword>
  <keyword>autologous T cell therapy</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>cell therapy</keyword>
  <keyword>liso-cel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

